- Home
- AGMB vs SD Comparison
AGMB vs SD Comparison
Compare AGMB & SD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGMB | SD |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | Belgium | United States |
| Employees | 62 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.4M | 502.8M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | AGMB | SD |
|---|---|---|
| Price | $11.69 | $13.99 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $32.00 | $15.00 |
| AVG Volume (30 Days) | 103.4K | ★ 331.0K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 3.07% |
| EPS Growth | N/A | ★ 12.43 |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.65 |
| Revenue Next Year | $17.86 | $1.75 |
| P/E Ratio | ★ N/A | $28.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.75 | $9.89 |
| 52 Week High | $17.82 | $18.45 |
Technical Indicators
Market Signals| Indicator | AGMB | SD |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 52.49 |
| Support Level | $11.53 | $13.85 |
| Resistance Level | $12.53 | $15.71 |
| Average True Range (ATR) | 1.01 | 0.33 |
| MACD | -0.22 | 0.10 |
| Stochastic Oscillator | 14.44 | 91.26 |
Price Performance
Historical ComparisonAbout AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.